State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists

International Urology and Nephrology

Volumn 47, Issue 9, 2015, Pages 1529-1539

  Covic, Adrian ^a   Abraham, Ivo ^b  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Anemia; Chronic kidney disease; End stage renal disease; Erythropoiesis stimulating agents; Hemodialysis

Indexed keywords

ANTIANEMIC AGENT; BIOSIMILAR AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; DRUG ANTIBODY; HEMOGLOBIN; NEUTRALIZING ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN;

ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG QUALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; END STAGE RENAL DISEASE; EUROPE; HEMODIALYSIS; HUMAN; HYPERTENSION; IMMUNOGENICITY; INFECTION; INFESTATION; MAXIMUM PLASMA CONCENTRATION; PATIENT SAFETY; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; COMPLICATION; DISEASE MANAGEMENT; RENAL INSUFFICIENCY, CHRONIC; UNITED STATES;

ANEMIA; BIOSIMILAR PHARMACEUTICALS; DISEASE MANAGEMENT; ERYTHROPOIETIN; EUROPE; HUMANS; RENAL INSUFFICIENCY, CHRONIC; UNITED STATES;

EID: 84940439672     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-015-1042-9     Document Type: Article

References (59)

1. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, van Aerts L, Vleminckx C, Wadhwa M, Schneider CK (2012) Biosimilars: what clinicians should know. Blood 120:5111–5117
2. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK (2014) Biosimilars: the science of extrapolation. Blood 124:3191–3196
3. Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (2012) US Food and Drug Administration. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 21 Jan 2014
4. Guidance for Industry Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product (2012) US Food and Drug Administration. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf. Accessed 21 Jan 2014
5. Guideline on Non-Clinical and Clinical Development of Similar Biologic Medicinal Products Containing Recombinant Erythropoietins (Revision) (2010) European Medicines Agency Committee for Medicinal Products for Human Use. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/04/WC500089474.pdf. Accessed 21 Jan 2014
6. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, Heim HK, Heinonen E, Ho K, Thorpe R, Vleminckx C, Wadhwa M, Schneider CK (2011) Biosimilars-why terminology matters. Nat Biotechnol 29:690–693
7. Guideline on Similar Biologic Medicinal Products (2005) EMEA Committee for Medicinal Products for Human Use. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf. Accessed 14 Jul 2014
8. Covic A, Cannata-Andia J, Cancarini G, Coppo R, Frazao JM, Goldsmith D, Ronco P, Spasovski GB, Stenvinkel P, Utas C, Wiecek A, Zoccali C, London G (2008) Biosimilars and biopharmaceuticals: what the nephrologists need to know—a position paper by the ERA-EDTA Council. Nephrol Dial Transplant 23:3731–3737
9. Epogen (epoetin alfa) package insert. (2011). Amgen, Inc., Thousand Oaks
10. Tsuda E, Goto M, Murakami A et al (1988) Comparative structural study of N-linked oligosaccharides of urinary and recombinant erythropoietins. Biochemistry 27:5646–5654
11. Davis JM, Arakawa T, Strickland TW, Yphantis DA (1987) Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 26:2633–2638
12. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, Lee J (1998) Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 100:79–89
13. Bennett WM (1991) A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol 1:990–998
14. Horl WH (2013) Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs 73:117–130
15. Locatelli F, Del Vecchio L (2008) Optimizing the management of renal anemia: challenges and new opportunities. Kidney Int Suppl 111:S33–S37
16. Goldsmith D (2010) 2009: a requiem for rHuEPOs—but should we nail down the coffin in 2010? Clin J Am Soc Nephrol 5:929–935
17. Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84(Suppl 1):3–10
18. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B (2006) Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 1:1211–1215
19. Boven K, Stryker S, Knight J, Thomas A, van Regenmortel M, Kemeny DM, Power D, Rossert J, Casadevall N (2005) The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 67:2346–2353
20. Schneider CK, Borg JJ, Ehmann F, Ekman N, Heinonen E, Ho K, Hoefnagel MH, van der Plas RM, Ruiz S, van der Stappen AJ, Thorpe R, Tiitso K, Tsiftsoglou AS, Vleminckx C, Waxenecker G, Welin M, Weise M, Trouvin JH, Working Party on Similar Biological (Biosimilar) Medicinal Products (BMWP), Biologicals Working Party (BWP) of the Committee for Medicinal Products for Human Use (2012) In support of the European Union biosimilar framework. Nat Biotechnol 30:745–748 author reply 748–749
21. Brinks V, Hawe A, Basmeleh AH, Joachin-Rodriguez L, Haselberg R, Somsen GW, Jiskoot W, Schellekens H (2011) Quality of original and biosimilar epoetin products. Pharm Res 28:386–393
22. Singh A (2013) Biosimilars—what are the issues? International Allegiance of Patient Organizations. http://www.patientsorganizations.org/showarticle.pl?id=766&n=37120. Accessed 10 May 2014
23. Combe C, Tredree RL, Schellekens H (2005) Biosimilar epoetins: an analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 25:954–962
24. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Jootar S, Intragumtornchai T, Tungsanga K, Teerapornlertratt T, Lumlertkul D, Townamchai N, Susantitaphong P, Katavetin P, Kanjanabuch T, Avihingsanon Y, Eiam-Ong S (2011) Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 80:88–92
25. Ahmed I, Kaspar B, Sharma U (2012) Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Clin Ther 34:400–419
26. Mikhail A, Farouk M (2013) Epoetin biosimilars in Europe: five years on. Adv Ther 30:28–40
27. Abraham I, MacDonald K (2012) Clinical safety of biosimilar recombinant human erythropoietins. Expert Opin Drug Saf 11:819–840
28. Bagalagel A, Mohammed A, MacDonald K, Abraham I (2013) Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia. Biosimilars 3:35–45
29. Abraham I, Sun D, Bagalagel A, Altyar A, Mohammed A, Tharmarajah S, MacDonald K (2013) Biosimilars in 3D: definition, development and differentiation. Bioengineered 4:203–206
30. Haag-Weber M, Eckardt KU, Horl WH, Roger SD, Vetter A, Roth K (2012) Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-alpha (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 77:8–17
31. Horl WH, Locatelli F, Haag-Weber M, Ode M, Roth K (2012) Prospective multicenter study of HX575 (biosimilar epoetin-alpha) in patients with chronic kidney disease applying a target hemoglobin of 10–12 g/dL. Clin Nephrol 78:24–32
32. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group (2008) Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin 24:625–637
33. Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A (2008) Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther 25:1215–1228
34. Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R, Epoetin Zeta Study Group (2008) Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin 24:1407–1415
35. Abraham I, MacDonald K (2012) Clinical efficacy and safety of HX575, a biosimilar recombinant human erythropoietin, in the management of anemia. Biosimilars 2:13–25
36. Jelkmann W (2007) Recombinant EPO production—points the nephrologist should know. Nephrol Dial Transpl 22:2749–2753
37. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM (1986) Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2:1175–1178
38. Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C (1987) Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J (Clin Res Ed) 295:1017–1020
39. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584–590
40. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, Investigators CHOIR (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098
41. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Investigators BEAT (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032
42. Summary of Product Characteristics, Retacrit epoetin zeta (2014) European Medicines Agency. http://www.medicines.org.uk/emc/medicine/21313/spc#CLINICAL_PRECAUTIONS. Accessed 10 May 2014
43. Summary of Product Characteristics, Binocrit epoetin alfa (2014) European Medicines Agency. http://www.medicines.org.uk/emc/medicine/21625/SPC/Binocrit+Solution+for+Injection+in+a+pre-filled+syringe/. Accessed 10 May 2014
44. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P (1996) Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 334:630–633
45. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N (2004) Pure red-cell aplasia and epoetin therapy. N Engl J Med 351:1403–1408
46. Peces R, de la Torre M, Alcazar R, Urra JM (1996) Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 335:523–524
47. Prabhakar SS, Muhlfelder T (1997) Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 47:331–335
48. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469–475
49. Eckardt KU, Casadevall N (2003) Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 18:865–869
50. Shimizu H, Saitoh T, Ota F, Jimbo T, Tsukada Y, Murakami H, Nojima Y (2011) Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol 126:114–118
51. Seidl A, Hainzl O, Richter M, Fischer R, Bohm S, Deutel B, Hartinger M, Windisch J, Casadevall N, London GM, Macdougall I (2012) Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res 29:1454–1467
52. Macdougall IC, Casadevall N, Locatelli F, Combe C, London GM, Di Paolo S, Kribben A, Fliser D, Messner H, McNeil J, Stevens P, Santoro A, De Francisco ALM, Percheson P, Potamianou A, Foucher A, Fife D, Mérit V, Vercammen E, on Behalf of the PRIMS study group (2015) Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transpl 30:451–460
53. Ebbers HC, Muenzberg M, Schellekens H (2012) The safety of switching between therapeutic proteins. Expert Opin Biol Ther 12:1473–1485
54. Horbrand F, Rottenkolber D, Fischaleck J, Hasford J (2014) Erythropoietin-induced treatment costs in patients suffering from renal anemia—a comparison between biosimilar and originator drugs. Gesundheitswesen 76:e79–e84
55. Horbrand F, Bramlage P, Fischaleck J, Hasford J, Brunkhorst R (2013) A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia. Eur J Clin Pharmacol 69:929–936
56. Krivoshiev et al (2010) Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther 27:105–117
57. Sorgel et al (2009) Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial. BMC Clin Pharmacol 9:10
58. Sorgel et al (2009) Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations. Pharmacology 83:122–130
59. Haag-Weber et al (2009) Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 72:380–390